Back to Search
Start Over
Positive effects on cardiovascular and breast metabolic markers of oral estradiol and dydrogesterone in comparison with transdermal estradiol and norethisterone acetate
- Source :
- Maturitas. 41:299-311
- Publication Year :
- 2002
- Publisher :
- Elsevier BV, 2002.
-
Abstract
- To assess differences in two sequential combined hormone replacement therapy (HRT) products on selected cardiovascular and breast metabolic markers. The products were different concerning the route of administration of estradiol and its combined progestin, either oral or transdermal, and the androgenic properties of progestogens, respectively, dydrogesterone and norethisterone acetate.One hundred and nineteen healthy non-hysterectomized postmenopausal women were included in this open, multi-center, two parallel group trial. They were randomized to a treatment of six 28-day cycles with oral estradiol sequentially combined with dydrogesterone (oE2/D10) or a sequential combination patch of estradiol plus norethisterone acetate (tdE/NETA). At baseline and after six cycles the high-density lipoprotein cholesterol (HDL-C), the sex hormone binding globulin (SHBG) and the total insulin-like growth factor-I (IGF-I) blood levels were determined by a central laboratory. A total of 89 women were compliant to the protocol.After six cycles, a statistically significant difference (P0.001) concerning HDL-C, SHBG and IGF-I levels was found between the two treatment groups. The HDL-C levels were increased in the oE2/D10 group and decreased in the tdE/NETA group, with a final difference of about 0.3 mmol/l. The oE2/D10 treatment induced a sharp increase (about 57 mmol/l) in SHBG levels. IGF-I levels decreased with both the products, but the difference in favor of the oE2/D10 treatment was of about 30 ng/ml. Moreover, patients on tdE/NETA with an IGF-I baseline value below the median showed an increase.Oral estradiol sequentially combined with dydrogesterone, a non-androgenic progestogen, induced positive changes of some cardiovascular (HDL-C) and breast (SHBG and IGF-I) metabolic markers. These effects were significantly different from those obtained with a transdermal estradiol associated to an androgenic progestogen.
- Subjects :
- medicine.medical_specialty
Norethisterone
medicine.drug_class
Administration, Oral
Dydrogesterone
Administration, Cutaneous
General Biochemistry, Genetics and Molecular Biology
Sex hormone-binding globulin
Sex Hormone-Binding Globulin
Internal medicine
medicine
Hormone replacement therapy (male-to-female)
Humans
Insulin-Like Growth Factor I
Estradiol
biology
business.industry
Cholesterol, HDL
Estrogen Replacement Therapy
Obstetrics and Gynecology
Middle Aged
medicine.disease
Norethisterone acetate
Postmenopause
Menopause
Norethindrone Acetate
Endocrinology
Estrogen
biology.protein
Female
Norethindrone
business
Progestin
medicine.drug
Subjects
Details
- ISSN :
- 03785122
- Volume :
- 41
- Database :
- OpenAIRE
- Journal :
- Maturitas
- Accession number :
- edsair.doi.dedup.....63254cd5a381f0a2358c983e52848e2d